POINT
is an Indiana-based radiopharmaceutical company that develops and commercializes radioligands for the treatment of cancer... Read morePOINT
is an Indiana-based radiopharmaceutical company that develops and commercializes radioligands for the treatment of cancer... Read more
News
Dec 29, 2023
MarketScreener
POINT: POINT Biopharma Global Inc.(NasdaqCM:PNT) dropped from S&P TMI Index
Dec 27, 2023
CNBC
POINT: Eli Lilly completes small buy of cancer drugmaker - the payoff may come later
Dec 19, 2023
Pharamceutical Technology
POINT: POINT's prostate cancer trial meets primary endpoint as Lilly's offer looms
Dec 18, 2023
BioPharma Dive
POINT: Point radiopharma drug results disappoint in prostate cancer study
Dec 18, 2023
MarketScreener
POINT: Eli Lilly: further extension of takeover bid for Point Biopharma Global
Dec 18, 2023
MarketScreener
POINT: Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023
Nov 20, 2023
MarketScreener
POINT: Eli Lilly: has extended its tender offer for Point Biopharma
Nov 17, 2023
MarketScreener
POINT: Point Biopharma Holders Resisting Eli Lilly Tender Offer
Nov 17, 2023
Americanbankingnews
POINT: FY2023 EPS Estimates for POINT Biopharma Global Inc. Lifted by Analyst (NASDAQ:PNT)
Nov 13, 2023
BioSpace
POINT: POINT Biopharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
POINT Competitors
1
2
3
4
5
6
7
8
9
10